| 000 | 01685 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517064411.0 | ||
| 264 | 0 | _c20171218 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1873-5010 | ||
| 024 | 7 |
_a10.1016/j.jcf.2015.10.006 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVanDevanter, Donald R | |
| 245 | 0 | 0 |
_aIV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. _h[electronic resource] |
| 260 |
_bJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society _c05 2016 |
||
| 300 |
_a372-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Intravenous |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aCystic Fibrosis _xcomplications |
| 650 | 0 | 4 | _aEpisode of Care |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aRespiratory Tract Infections _xdrug therapy |
| 650 | 0 | 4 |
_aRisk Assessment _xmethods |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSymptom Flare Up |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 700 | 1 | _aMorris, Nathan J | |
| 700 | 1 | _aKonstan, Michael W | |
| 773 | 0 |
_tJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society _gvol. 15 _gno. 3 _gp. 372-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jcf.2015.10.006 _zAvailable from publisher's website |
| 999 |
_c25482341 _d25482341 |
||